On Monday, Processa Pharmaceuticals Inc (NASDAQ: PCSA) opened lower -4.76% from the last session, before settling in for the closing price of $3.78. Price fluctuations for PCSA have ranged from $2.74 to $27.00 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 22.65% over the past five years. Company’s average yearly earnings per share was noted 89.41% at the time writing. With a float of $2.00 million, this company’s outstanding shares have now reached $2.11 million.
Processa Pharmaceuticals Inc (PCSA) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Processa Pharmaceuticals Inc is 11.62%, while institutional ownership is 3.14%. The most recent insider transaction that took place on Jan 27 ’25, was worth 9,889. In this transaction Director of this company bought 12,400 shares at a rate of $0.80, taking the stock ownership to the 12,400 shares. Before that another transaction happened on Jan 27 ’25, when Company’s Chief Executive Officer bought 87,200 for $0.80, making the entire transaction worth $69,542. This insider now owns 87,200 shares in total.
Processa Pharmaceuticals Inc (PCSA) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -18.5 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -23) by 4.5.
According to the Wall Street analysts, stocks earnings will be around 89.41% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 62.14% during the next five years compared to 22.65% growth over the previous five years of trading.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Trading Performance Indicators
Check out the current performance indicators for Processa Pharmaceuticals Inc (PCSA). In the past quarter, the stock posted a quick ratio of 3.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -34.02, a number that is poised to hit -1.25 in the next quarter and is forecasted to reach -6.00 in one year’s time.
Technical Analysis of Processa Pharmaceuticals Inc (PCSA)
Processa Pharmaceuticals Inc (NASDAQ: PCSA) saw its 5-day average volume 8.78 million, a positive change from its year-to-date volume of 0.52 million. As of the previous 9 days, the stock’s Stochastic %D was 16.65%.
During the past 100 days, Processa Pharmaceuticals Inc’s (PCSA) raw stochastic average was set at 7.50%, which indicates a significant decrease from 14.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.26 in the past 14 days, which was higher than the 0.86 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.29, while its 200-day Moving Average is $6.74. Nevertheless, the first resistance level for the watch stands at $4.07 in the near term. At $4.53, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.77. If the price goes on to break the first support level at $3.37, it is likely to go to the next support level at $3.13. Assuming the price breaks the second support level, the third support level stands at $2.67.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Key Stats
There are currently 2,266K shares outstanding in the company with a market cap of 8.15 million. Presently, the company’s annual sales total 0 K according to its annual income of -11,850 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -3,440 K.
